Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
Breast cancer
Neoadjuvant chemotherapy
Neutrophil-to-lymphocyte ratio
Pathologic complete response
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
01
05
2022
accepted:
25
07
2022
pubmed:
19
8
2022
medline:
22
3
2023
entrez:
18
8
2022
Statut:
ppublish
Résumé
Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to NAC is an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood is associated with prognosis in various malignancies. Here, we investigated the value of the pretreatment NLR as a response predictor in neoadjuvant-treated patients with BC. A retrospective chart analysis of 862 patients with invasive BC treated with NAC at the Heidelberg University Hospital during 2003-2015 was conducted. NLR was calculated as the ratio of the absolute neutrophil and lymphocyte counts in peripheral blood, and pCR was defined as absence of invasive or in situ carcinoma in breast and axillary lymph nodes. A total of 151 patients with invasive BC who underwent NAC were included in this study. NLR tended to be higher in the pCR group than the non-pCR group (p < 0.1). Analyses of BC subtypes demonstrated that NLR was significantly higher in the pCR- compared with the non-pCR group (3.304 vs. 2.379, respectively; p = 0.048) in patients with luminal B/Her2-negative tumors. Further, we found a significant difference in NLR according to remission status in postmenopausal patients (2.861 vs. 2.313, respectively; p = 0.043). NLR was significantly higher only for patients achieving pCR in the Luminal B/Her2-negative and postmenopausal subgroups. Hence, NLR is a candidate additional predictive factor in patients with Luminal B/Her2-negative BC.
Identifiants
pubmed: 35980458
doi: 10.1007/s00404-022-06726-7
pii: 10.1007/s00404-022-06726-7
pmc: PMC10023763
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1113Informations de copyright
© 2022. The Author(s).
Références
Institut RK (2018) Breast Cancer. http://www.krebsdaten.de/Krebs/EN/Content/Cancer_sites/Breast_cancer/breast_cancer_node.html . Accessed 30 Dec 2018
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol Off J Eur Soc Med Oncol 26(8):1533–1546. https://doi.org/10.1093/annonc/mdv221
doi: 10.1093/annonc/mdv221
Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ (Clin Res ed) 351:h4901. https://doi.org/10.1136/bmj.h4901
doi: 10.1136/bmj.h4901
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/jco.2011.38.8595
doi: 10.1200/jco.2011.38.8595
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England) 384(9938):164–172. https://doi.org/10.1016/s0140-6736(13)62422-8
doi: 10.1016/s0140-6736(13)62422-8
pubmed: 24529560
Cortazar P, Geyer CE Jr (2015) Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 22(5):1441–1446. https://doi.org/10.1245/s10434-015-4404-8
doi: 10.1245/s10434-015-4404-8
pubmed: 25727556
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147
doi: 10.1200/jco.2007.14.4147
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88(1):218–230. https://doi.org/10.1016/j.critrevonc.2013.03.010
doi: 10.1016/j.critrevonc.2013.03.010
pubmed: 23602134
Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG (2012) Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res 32(4):1555–1561
pubmed: 22493401
Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31(9):2995–2998
pubmed: 21868550
Noh H, Eomm M, Han A (2013) Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 16(1):55–59. https://doi.org/10.4048/jbc.2013.16.1.55
doi: 10.4048/jbc.2013.16.1.55
pubmed: 23593082
pmcid: 3625770
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19(1):217–224. https://doi.org/10.1245/s10434-011-1814-0
doi: 10.1245/s10434-011-1814-0
pubmed: 21638095
Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N (2019) Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast (Edinburgh, Scotland) 44:33–38. https://doi.org/10.1016/j.breast.2018.12.014
doi: 10.1016/j.breast.2018.12.014
pubmed: 30611095
Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil- to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124
doi: 10.1093/jnci/dju124
pubmed: 24875653
Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (Baltimore, Md: 1950) 162(10):5728–5737
doi: 10.4049/jimmunol.162.10.5728
Benelli R, Albini A, Noonan D (2003) Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. Chem Immunol Allergy 83:167–181
doi: 10.1159/000071560
pubmed: 12947984
Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP (2001) Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 280(4):C814-822. https://doi.org/10.1152/ajpcell.2001.280.4.C814
doi: 10.1152/ajpcell.2001.280.4.C814
pubmed: 11245598
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol Off J Eur Soc Med Oncol 24(9):2206–2223. https://doi.org/10.1093/annonc/mdt303
doi: 10.1093/annonc/mdt303
Ivars Rubio A et al (2019) Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independant predictor of survival, but depends on other variables. Sci Rep 9(1):16979
doi: 10.1038/s41598-019-53606-3
pubmed: 31740715
pmcid: 6861311
Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, Campian JL (2019) Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer. Breast Cancer Res Treat 174(2):443–452. https://doi.org/10.1007/s10549-018-05106-7
doi: 10.1007/s10549-018-05106-7
pubmed: 30604000
Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, Loibner H, Dandachi N, Balic M (2015) Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. BMC Cancer 15:1027. https://doi.org/10.1186/s12885-015-2005-3
doi: 10.1186/s12885-015-2005-3
pubmed: 26715527
pmcid: 4696229
Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Hirakawa K, Ohira M (2018) Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer 18(1):1137. https://doi.org/10.1186/s12885-018-5051-9
doi: 10.1186/s12885-018-5051-9
pubmed: 30453914
pmcid: 6245848
Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, Garcia-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F (2016) High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer. Oncologist 21(2):150–155. https://doi.org/10.1634/theoncologist.2015-0312
doi: 10.1634/theoncologist.2015-0312
pubmed: 26786263
pmcid: 4746087
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304
doi: 10.1093/annonc/mdr304
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764
doi: 10.1056/NEJMoa1510764
pubmed: 26412349
pmcid: 4701034
Reyal F, Hamy A, Piccart MJ (2018) Neoadjuvant treatment: the future of patients with breast cancer. ESMO Open 3(4):e000371. https://doi.org/10.1136/esmoopen-2018-000371
doi: 10.1136/esmoopen-2018-000371
pubmed: 29862051
pmcid: 5976132